search
Back to results

Improving CarE for Community Acquired Pneumonia 1 (ICE-CAP1)

Primary Purpose

Pneumonia Childhood

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Clinical Decision Support
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Pneumonia Childhood

Eligibility Criteria

6 Months - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Six months to <18 years of age
  • Radiographic evidence of pneumonia in ED (via natural language processing)
  • Provider-confirmed diagnosis of pneumonia (via Clinical Decision Support (CDS))

Exclusion Criteria:

  • Children with tracheostomy, cystic fibrosis, immunosuppression
  • Inter-hospital transfers
  • Hospitalization within preceding 7 days
  • Previously enrolled within preceding 28 days
  • Provider preference for any reason

Sites / Locations

  • Monroe Carell Jr. Children's Hospital - Vanderbilt University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention Arm

Control Arm

Arm Description

The antibiotic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive usual care and all treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.

No experimental decision support will be provided to those randomized to the control arm. All children will receive usual care and treatment will not be restricted or altered in any way by the study.

Outcomes

Primary Outcome Measures

Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours
The primary outcome is the percentage of children in which ALL antibiotic treatment prescribed in the first 24 hours of the encounter is guideline-concordant.

Secondary Outcome Measures

Exclusive Guideline-Concordant Antibiotic Prescribing, Entire Episode
This secondary outcome reports encounters in which established antibiotic stewardship guidelines are followed for ALL prescribing for the duration of the encounter (ED triage through hospital discharge).
Any Guideline-Concordant Antibiotic Prescribing, First 24 Hours
This secondary outcome includes ANY guideline-concordant prescribing during the first 24 hours of the encounter.
Any Guideline-Concordant Antibiotic Prescribing, Entire Episode
This secondary outcome includes ANY guideline-concordant prescribing during the ENTIRE encounter (ED triage through hospital discharge).

Full Information

First Posted
September 15, 2018
Last Updated
November 9, 2022
Sponsor
Vanderbilt University Medical Center
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03760419
Brief Title
Improving CarE for Community Acquired Pneumonia 1
Acronym
ICE-CAP1
Official Title
Improving CarE for Community Acquired Pneumonia 1 (ICE-CAP1): Antibiotic Decision Support
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
December 17, 2018 (Actual)
Primary Completion Date
September 30, 2020 (Actual)
Study Completion Date
September 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Children with pneumonia presenting to the emergency department at Monroe Carell Jr. Children's Hospital at Vanderbilt or Children's Hospital of Pittsburgh will be potentially eligible for study. During intervention periods, providers caring for enrolled children will be presented with a detailed decision support strategy that emphasizes management in accordance with national guideline recommendations. The anticipated study duration is 18 months and, as this study does not include direct contact with enrolled subjects, there is no anticipated follow up.
Detailed Description
Pneumonia is the most common serious infection in childhood. In the United States (US), pneumonia accounts for 1-4% of all emergency department (ED) visits in children (3-28 per 1,000 US children per year) and ranks among the top 3 reasons for pediatric hospitalization with >100,000 hospitalizations per year (15-22 per 100,000 US children per year)2-5. Pneumonia also accounts for more days of antibiotic use in US children's hospitals than any other condition. Safely reducing inappropriate antibiotic use is critical to slow the progression of antimicrobial resistance, and childhood pneumonia is a key area where substantial improvements can be made. In the 2011 Pediatric Infectious Diseases Society/Infectious Diseases Society of America (PIDS/IDSA) pneumonia guideline, appropriate use of antibiotics was an important area of emphasis. For presumed bacterial pneumonia, recommendations emphasize the use of a single, narrow-spectrum antibiotic (i.e. amoxicillin or ampicillin). In children <6 years of age treated in the outpatient setting, the guideline recommended considering withholding antibiotics, recognizing that pneumonia in this population is most often caused by viruses. Both of these recommendations were graded as strong and supported by high-quality evidence. Nonetheless, in a large database study we conducted just prior to release of the 2011 guideline, use of broad-spectrum antibiotics was very common among children hospitalized with pneumonia, with substantial differences in antibiotic selection patterns among the various hospitals. In that study, use of narrow-spectrum ampicillin was rare (<5%). High rates of broad-spectrum antibiotic use were also noted in a study of children with pneumonia treated and released from US EDs, with <30% of children receiving narrow-spectrum therapy. Study Aim: To test the hypothesis that electronic antibiotic decision support increases guideline-concordant antibiotic use compared with usual care in the emergency department. The primary outcome is the proportion of children exclusively receiving guideline-concordant first line antibiotic therapy during the first 24 hours of care. Secondary outcomes include exclusive use of concordant antibiotic therapy for the entire episode, any use of concordant antibiotic therapy during the first 24 hours of care and for the entire episode, and emergency department revisits and hospitalizations within 72 hours and 7 days of the index discharge. In this study, conducted at two experienced academic centers, the investigator will implement and evaluate an electronic health record based clinical decision support application to promote antibiotic use in concordance with the 2011 PIDS/IDSA guideline in a pragmatic, cluster randomized trial. Decisions regarding management, including antibiotic selection and site of care, will be at the discretion of the treating provider and will not be restricted or altered in any way. Thus, this study poses no greater than minimal risks to participants. Due to the nature of the research, waiver of informed consent has been provided, as it has been done in similar pragmatic studies at the institutions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pneumonia Childhood

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Effectiveness of the EHR-based antibiotic decision support application for promoting guideline-concordant antibiotic prescribing in children presenting for emergency care will be evaluated in a pragmatic, cluster-randomized study conducted over a period of 18 months that includes two respiratory seasons. Randomization will occur monthly at each hospital. To ensure balanced representation of each arm in periods of both low and high pneumonia prevalence, randomization will occur in 3 permuted blocks (size=6).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1027 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention Arm
Arm Type
Experimental
Arm Description
The antibiotic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive usual care and all treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.
Arm Title
Control Arm
Arm Type
No Intervention
Arm Description
No experimental decision support will be provided to those randomized to the control arm. All children will receive usual care and treatment will not be restricted or altered in any way by the study.
Intervention Type
Behavioral
Intervention Name(s)
Clinical Decision Support
Intervention Description
For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
Primary Outcome Measure Information:
Title
Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours
Description
The primary outcome is the percentage of children in which ALL antibiotic treatment prescribed in the first 24 hours of the encounter is guideline-concordant.
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Exclusive Guideline-Concordant Antibiotic Prescribing, Entire Episode
Description
This secondary outcome reports encounters in which established antibiotic stewardship guidelines are followed for ALL prescribing for the duration of the encounter (ED triage through hospital discharge).
Time Frame
18 months
Title
Any Guideline-Concordant Antibiotic Prescribing, First 24 Hours
Description
This secondary outcome includes ANY guideline-concordant prescribing during the first 24 hours of the encounter.
Time Frame
18 months
Title
Any Guideline-Concordant Antibiotic Prescribing, Entire Episode
Description
This secondary outcome includes ANY guideline-concordant prescribing during the ENTIRE encounter (ED triage through hospital discharge).
Time Frame
18 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Six months to <18 years of age Radiographic evidence of pneumonia in ED Provider-confirmed diagnosis of pneumonia (via Clinical Decision Support [CDS]) Exclusion Criteria: Children with tracheostomy, cystic fibrosis, immunosuppression Inter-hospital transfers Hospitalization within preceding 7 days Previously enrolled within preceding 28 days Provider preference for any reason
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Derek J Williams, MD, MPH
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Monroe Carell Jr. Children's Hospital - Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Improving CarE for Community Acquired Pneumonia 1

We'll reach out to this number within 24 hrs